Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 13/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6932932 | 0.92 | MDM2 (0.38) | MDM2MAPTGSK3BGSK3AALDH1A1 | |
| SCHEMBL6932901 | 0.85 | PGR (0.41) | SMN1; SMN2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL7966269 | 0.81 | LMNA (0.40) | MDM2HTTSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7968407 | 0.79 | POLB (0.46) | KDM4EHTTSMN1; SMN2MAPTGSK3B | |
| SCHEMBL7586371 | 0.77 | AKR1C2 (0.41) | SMN1; SMN2MAPTALDH1A1MEN1POLB | |
| SCHEMBL6934449 | 0.77 | AKR1C2 (0.41) | SMN1; SMN2MAPTALDH1A1MEN1POLB | |
| SCHEMBL6931685 | 0.74 | PGR (0.43) | ALDH1A1 | |
| SCHEMBL7539856 | 0.74 | ABCG2 (0.37) | MAPTPOLBRAB9A | |
| SCHEMBL7968467 | 0.74 | MAPT (0.39) | HTTMAPTALDH1A1MEN1NPC1 | |
| SCHEMBL7966642 | 0.74 | CYP1A2 (0.41) | SMN1; SMN2MAPTALDH1A1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6265436-B1 | ANTIINFLAMMATORY AGENTS | OXIS THERAPEUTICS INC. | 2001-07-24 | — | — | US | claimed |
| EP-1246811-B1 | METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES | OXIS ISLE OF MAN LTD (GB) | 2003-12-03 | — | — | EP | disclosed |
| US-6613919-B2 | Resolution with enantiomerically pure bases such as cinchonidine by forming a salt; also 3,4-dihydroxy-2(5H)-furanones | OXIS ISLE OF MAN | 2003-09-02 | — | — | US | disclosed |
| US-20030065196-A1 | Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones | OXIS ISLE OF MAN | 2003-04-03 | — | — | US | disclosed |
| EP-1246811-A1 | METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES | OXIS Isle of Man, Limited (GB) | 2002-10-09 | — | — | EP | disclosed |
| US-6265436-B1 | ANTIINFLAMMATORY AGENTS | OXIS THERAPEUTICS INC. | 2001-07-24 | — | — | US | disclosed |
| WO-2001049671-A1 | METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES | OXIS ISLE OF MAN, LIMITED (US) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065196-A1 | Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones | ADH1C, SRD5A2, SRD5A1 | MDM2 1077/4885KDM4E 2874/4885HTT 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.